journal
MENU ▼
Read by QxMD icon Read
search

Molecular Oncology

journal
https://www.readbyqxmd.com/read/28432815/immunoassays-for-the-quantification-of-alk-and-phosphorylated-alk-support-the-evaluation-of-on-target-alk-inhibitors-in-neuroblastoma
#1
Elizabeth R Tucker, Jennifer R Tall, Laura S Danielson, Sharon Gowan, Yann Jamin, Simon P Robinson, Udai Banerji, Louis Chesler
Targeted inhibition of Anaplastic Lymphoma Kinase (ALK) is a successful approach for the treatment of many ALK-aberrant malignancies, however the presence of resistant mutations necessitates both the development of more potent compounds and pharmacodynamic methods with which to determine their efficacy. We describe immunoassays designed to quantitate phosphorylation of ALK, and their use in preclinical models of neuroblastoma, a pediatric malignancy in which gain-of-function ALK mutations predict a poor overall outcome to conventional treatment...
April 22, 2017: Molecular Oncology
https://www.readbyqxmd.com/read/28423230/gain-of-function-p53-activates-multiple-signaling-pathways-to-induce-oncogenicity-in-lung-cancer-cells
#2
Catherine A Vaughan, Shilpa Singh, Steven R Grossman, Brad Windle, Swati P Deb, Sumitra Deb
Gain of function (GOF) mutants of p53 upregulate genes implicated in cell proliferation and oncogenesis. Here we report that GOF p53 induces tumorigenicity through simultaneous activation of key oncogenic pathways including those controlling putative tumor-initiating cell functions. We determined that in cells expressing p53-R273H, GOF p53 simultaneously up-regulates genes from multiple signaling pathways by recognizing promoters containing distinct transcription factor binding sites. Our analytical data support a model in which GOF p53 complexes with two transcription factors on the promoter - a mediator protein, Med17, and a histone acetyl transferase, activating histone acetylation - and enhances gene expression to signal cell proliferation and oncogenesis...
April 18, 2017: Molecular Oncology
https://www.readbyqxmd.com/read/28417568/cisplatin-resistant-cancer-cells-are-sensitive-to-aurora-kinase-a-inhibition-by-alisertib
#3
Lihong Wang, Janet Arras, Ahmed Katsha, Saif Hamdan, Abbes Belkhiri, Jeffrey Ecsedy, Wael El-Rifai
De novo and acquired resistance to platinum therapy such as cisplatin (CDDP) is a clinical challenge in gastric cancer treatment. Aberrant expression and activation of Aurora kinase A (AURKA) and eukaryotic translation initiation factor 4E (eIF4E) are detected in several cancer types. Herein, we investigated the role of AURKA in CDDP resistance in gastric cancer. Western blot analysis demonstrated overexpression of AURKA and phosphorylation of eIF4E in acquired and de novo CDDP-resistant gastric cancer models...
April 18, 2017: Molecular Oncology
https://www.readbyqxmd.com/read/28417539/usp22-mediates-the-multidrug-resistance-of-hepatocellular-carcinoma-via-the-sirt1-akt-mrp1-signaling-pathway
#4
Sunbin Ling, Jie Li, Qiaonan Shan, Haojiang Dai, Di Lu, Xue Wen, Penghong Song, Haiyang Xie, Lin Zhou, Jimin Liu, Xiao Xu, Shusen Zheng
Drug treatments for hepatocellular carcinoma (HCC) often fail because of multidrug resistance (MDR). The mechanisms of MDR are complex but cancer stem cells (CSC), which are able to self-renew and differentiate, have recently been shown to be involved. The deubiquitinating enzyme ubiquitin-specific protease 22 (USP22) is a marker for CSCs. This study aimed to elucidate the role of USP22 in MDR of HCC and the underlying mechanisms. Using in vitro and in vivo assays, we found that modified USP22 levels were responsible for the altered drug-resistant phenotype of BEL7402 and BEL/FU cells...
April 18, 2017: Molecular Oncology
https://www.readbyqxmd.com/read/28397399/belinostat-exerts-anti-tumor-cytotoxicity-through-the-ubiquitin-proteasome-pathway-in-lung-squamous-cell-carcinoma
#5
Li Ren Kong, Tuan Zea Tan, Weijie Richard Ong, Chonglei Bi, Hung Huynh, Soo Chin Lee, Wee Joo Chng, Pieter Johan Adam Eichhorn, Boon Cher Goh
There have been advances in personalized therapy directed by molecular profiles in lung adenocarcinoma but not in lung squamous cell carcinoma (SCC). The lack of actionable driver oncogenes in SCC has restricted the use of small molecule inhibitors. Here, we show that SCC cell lines displayed differential sensitivities to belinostat, a pan-histone deacetylase (HDAC) inhibitor. Phosphoproteomic analysis of belinostat-treated SCC cells revealed significant downregulation of the MAPK pathway, along with induction of apoptosis...
April 11, 2017: Molecular Oncology
https://www.readbyqxmd.com/read/28388012/methylation-profiling-of-paediatric-pilocytic-astrocytoma-reveals-variants-specifically-associated-with-tumour-location-and-predictive-of-recurrence
#6
Alexandra Sexton-Oates, Andrew Dodgshun, Volker Hovestadt, David T W Jones, David M Ashley, Michael Sullivan, Duncan MacGregor, Richard Saffery
Childhood pilocytic astrocytomas (PA) are low grade tumours with an excellent prognosis. However, a minority, particularly those in surgically inaccessible locations, have poorer long term outcome. At present it is unclear whether anatomical location in isolation, or in combination with underlying biological variation, determines clinical behaviour. Here we have tested the utility of DNA methylation profiling to inform tumour biology and to predict behaviour in paediatric PA. Genome-wide DNA methylation profiles were generated for 117 paediatric PAs...
April 7, 2017: Molecular Oncology
https://www.readbyqxmd.com/read/28388009/triplet-therapy-with-afatinib-cetuximab-and-bevacizumab-induces-deep-remission-in-lung-cancer-cells-harboring-egfr-t790m-in-vivo
#7
Kenichiro Kudo, Kadoaki Ohashi, Go Makimoto, Hisao Higo, Yuka Kato, Hiroe Kayatani, Yasuko Kurata, Yoichiro Takami, Daisuke Minami, Takashi Ninomiya, Toshio Kubo, Eiki Ichihara, Akiko Sato, Katsuyuki Hotta, Tadashi Yoshino, Mitsune Tanimoto, Katsuyuki Kiura
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have changed the treatment strategy for EGFR-mutant lung cancers; however, resistance usually occurs due to a secondary mutation, T790M, in EGFR. Combination therapy using afatinib and cetuximab has had good results in lung tumors harboring EGFR(T)(790M) mutations in clinical trials. The effect of bevacizumab, an anti-vascular endothelial growth factor (VEGF) antibody, combined with EGFR-TKIs has also been investigated. We hypothesized that the dosage of afatinib and cetuximab could be reduced by combination with bevacizumab, and that the triplet therapy may result in better tumor inhibition with tolerable toxicity...
April 7, 2017: Molecular Oncology
https://www.readbyqxmd.com/read/28383788/replication-stress-dna-damage-signalling-and-cytomegalovirus-infection-in-human-medulloblastomas
#8
Jiri Bartek, Olesja Fornara, Joanna Maria Merchut-Maya, Apolinar Maya-Mendoza, Afshar Rahbar, Giuseppe Stragliotto, Helle Broholm, Mikael Svensson, Astrid Sehested, Cecilia Söderberg Naucler, Jiri Bartek, Jirina Bartkova
Medulloblastomas are the most common, and often fatal, paediatric brain tumours that feature high genomic instability, frequent infection by human cytomegalovirus (HCMV) and resistance to radiation and chemotherapy. The causes of the pronounced chromosomal instability and its potential links with HCMV infection and/or resistance to genotoxic therapies remain largely unknown. To address these issues, here we have combined immunohistochemical analysis of a series of 25 paediatric medulloblastomas, complemented by medulloblastoma cell culture models including experimental HCMV infection...
April 6, 2017: Molecular Oncology
https://www.readbyqxmd.com/read/28378523/impact-of-somatic-copy-number-alterations-on-the-glioblastoma-mirnome-mir-4484-is-a-genomically-deleted-tumour-suppressor
#9
Zahid Nawaz, Vikas Patil, Sivaarumugam Thinagararjan, Soumya A Rao, Alangar S Hegde, Arimappamagan Arivazhagan, Vani Santosh, Kumaravel Somasundaram
Glioblastoma (GBM) is the most frequent and most malignant primary brain tumour in adults. GBMs have a unique landscape of somatic copy number alterations (SCNAs), with the concomitant appearance of numerous driver amplifications and deletions. Here, we examined the genomic regions harbouring SCNAs and their impact on the GBM miRNome. We found that 40% of SCNA events covering 70-88% of the genomically altered regions, as identified by GISTIC and RAE algorithms, carried miRNA genes. Out of 1426 annotated mature miRNAs analysed, ~ 14% (n=198) were mapped to such fragile loci...
April 5, 2017: Molecular Oncology
https://www.readbyqxmd.com/read/28371345/the-prostate-metastasis-suppressor-gene-ndrg1-differentially-regulates-cell-motility-and-invasion
#10
Anup Sharma, Janet Mendonca, James Ying, Hea-Soo Kim, James E Verdone, Jelani C Zarif, Michael Carducci, Hans Hammers, Kenneth J Pienta, Sushant Kachhap
Experimental and clinical evidence suggests that N-myc downregulated gene 1 (NDRG1) functions as a suppressor of prostate cancer metastasis. Elucidating pathways that drive survival and invasiveness of NDRG1-deficient prostate cancer cells can help in designing therapeutics to target metastatic prostate cancer cells. However, the molecular mechanism(s) that lead NDRG1-deficient prostate cancer cells to increased invasiveness remains largely unknown. In this study, we demonstrate that NDRG1-deficient prostate tumors have decreased integrin expression and reduced cell adhesion and motility...
April 2, 2017: Molecular Oncology
https://www.readbyqxmd.com/read/28371273/fen1-promotes-tumor-progression-and-confers-cisplatin-resistance-in-non-small-cell-lung-cancer
#11
Lingfeng He, Libo Luo, Hong Zhu, Huan Yang, Yilan Zhang, Huan Wu, Hongfang Sun, Feng Jiang, Chandra Sekhar Kathera, Lingjie Liu, Ziheng Zhuang, Haoyan Chen, Feiyan Pan, Zhigang Hu, Jing Zhang, Zhigang Guo
Lung cancer is one of the leading causes of cancer mortality worldwide. The therapeutic effect of chemotherapy is limited due to the resistance of cancer cells, which remains a challenge in cancer therapeutics. In this work, we found that flap endonuclease 1 (FEN1) is overexpressed in lung cancer cells. FEN1 is a major component of the base excision repair (BER) pathway for DNA repair systems and plays important roles in maintaining genomic stability through DNA replication and repair. We showed that FEN1 is critical for the rapid proliferation of lung cancer cells...
March 29, 2017: Molecular Oncology
https://www.readbyqxmd.com/read/28319320/the-endochondral-bone-protein-chm1-sustains-an-undifferentiated-invasive-phenotype-promoting-lung-metastasis-in-ewing-sarcoma
#12
Kristina von Heyking, Julia Calzada-Wack, Stefanie Göllner, Frauke Neff, Oxana Schmidt, Tim Hensel, David Schirmer, Annette Fasan, Irene Esposito, Carsten Müller-Tidow, Poul H Sorensen, Stefan Burdach, Günther H S Richter
Ewing sarcomas (ES) are highly malignant, osteolytic bone or soft tissue tumors, which are characterized by EWS-ETS translocations and early metastasis to lung and bone. In this study, we investigated the role of the BRICHOS chaperone domain-containing endochondral bone protein chondromodulin I (CHM1) in ES pathogenesis. CHM1 is significantly over-expressed in ES, and chromosome immunoprecipitation (ChIP) data demonstrate CHM1 to be directly bound by an EWS-ETS translocation, EWS-FLI1. Using RNA interference we observed that CHM1 promoted chondrogenic differentiation capacity of ES cells but decreased the expression of osteolytic genes such as HIF1A, IL6, JAG1 and VEGF...
March 20, 2017: Molecular Oncology
https://www.readbyqxmd.com/read/28306193/diphtheria-toxin-based-anti-human-cd19-immunotoxin-for-targeting-human-cd19-tumors
#13
Qian Zheng, Zhaohui Wang, Huiping Zhang, Qi Huang, Joren C Madsen, David H Sachs, Christene A Huang, Zhirui Wang
CD19 is expressed on normal and neoplastic B cells and is a promising target for immunotherapy. However, there is still an unmet need to further develop novel therapeutic drugs for the treatment of the refractory/relapsing human CD19(+) tumors. We have developed a diphtheria toxin-based anti-human CD19 immunotoxin for targeting human CD19(+) tumors. We have constructed three isoforms of the CD19 immunotoxin: monovalent, bivalent and foldback diabody. In vitro binding affinity and efficacy analysis demonstrated that the bivalent isoform had the highest binding affinity and in vitro efficacy...
March 17, 2017: Molecular Oncology
https://www.readbyqxmd.com/read/28306192/histone-deacetylase-activity-mediates-acquired-resistance-towards-structurally-diverse-hsp90-inhibitors
#14
Ryan C Chai, Jessica L Vieusseux, Benjamin J Lang, Chau H Nguyen, Michelle M Kouspou, Kara L Britt, John T Price
Heat Shock Protein 90 (HSP90) regulates multiple signaling pathways critical for tumor growth. As such, HSP90 inhibitors have been shown to act as effective anticancer agents in preclinical studies but, for a number of reasons, the same effect has not been observed in the clinical trials to date. One potential reason for this may the presence of de novo or acquired resistance within the tumors. To investigate mechanisms of resistance, we generated resistant cell lines through gradual dose escalation of the HSP90 inhibitor 17-AAG...
March 17, 2017: Molecular Oncology
https://www.readbyqxmd.com/read/28306189/map4k4-is-a-novel-mapk-erk-pathway-regulator-required-for-lung-adenocarcinoma-maintenance
#15
Xuan Gao, Guangming Chen, Chenxi Gao, Dennis Han Zhang, Shih-Fan Kuan, Laura P Stabile, Guoxiang Liu, Jing Hu
About 76% of lung adenocarcinoma patients harbor activating mutations in the receptor tyrosine kinase (RTK)/RAS/RAF pathways, leading to aberrant activation of the MAPK pathways particularly the MAPK/ERK pathway. However, many lung adenocarcinomas lacking these genomic mutations also display significant MAPK pathway activation, suggesting that additional MAPK pathway alterations remain undetected. This study has identified serine/threonine kinase mitogen-activated protein 4 kinase 4 (MAP4K4) as a novel positive regulator of MAPK/ERK signaling in lung adenocarcinoma...
March 17, 2017: Molecular Oncology
https://www.readbyqxmd.com/read/28296140/inhibitors-of-stat3-%C3%AE-catenin-and-igf-1r-sensitize%C3%A2-mouse-pik3ca%C3%A2-mutant%C3%A2-breast-cancer-to-pi3k-inhibitors
#16
Vanessa F Merino, Soonweng Cho, Xiaohui Liang, Sunju Park, Kideok Jin, Qian Chen, Duojia Pan, Cynthia A Zahnow, Alan R Rein, Saraswati Sukumar
Although mutations in the phosphoinositide 3-kinase-catalytic subunit (PIK3CA) are common in breast cancer, PI3K inhibitors alone have shown modest efficacy. We sought to identify additional pathways altered in PIK3CA mutant tumors that might be targeted in combination with PI3K inhibitors. We generated two transgenic mouse models expressing the human PIK3CA-H1047R and the -E545K hotspot mutant genes in the mammary gland and evaluated their effects on development and tumor formation. Molecular analysis identified pathways altered in these mutant tumors, which were also targeted in multiple cells lines derived from the PIK3CA tumors...
March 15, 2017: Molecular Oncology
https://www.readbyqxmd.com/read/28296343/a-genome-wide-sirna-screen-for-regulators-of-tumor-suppressor-p53-activity-in-human-non-small-lung-cancer-cells-identifies-components-of-the-rna-splicing-machinery-as-targets-for-anticancer-treatment
#17
Ellen Siebring-van Olst, Maxime Blijlevens, Renee X de Menezes, Ida H van der Meulen-Muileman, Egbert F Smit, Victor W van Beusechem
Reinstating wild-type tumor suppressor p53 activity could be a valuable option for the treatment of cancer. To contribute to development of new treatment options for non-small cell lung cancer (NSCLC), we performed genome-wide siRNA screens for determinants of p53 activity in NSCLC cells. We identified many genes not previously known to be involved in regulating p53 activity. Silencing p53 pathway inhibitor genes was associated with loss of cell viability. The largest functional gene cluster influencing p53 activity was mRNA splicing...
March 13, 2017: Molecular Oncology
https://www.readbyqxmd.com/read/28296148/dimp53-1-a-novel-small-molecule-dual-inhibitor-of-p53-mdm2-x-interactions-with-multifunctional-p53-dependent-anticancer-properties
#18
Joana Soares, Margarida Espadinha, Liliana Raimundo, Helena Ramos, Ana Sara Gomes, Sara Gomes, Joana B Loureiro, Alberto Inga, Flávio Reis, Célia Gomes, Maria M M Santos, Lucília Saraiva
The transcription factor p53 plays a crucial role in cancer development and dissemination, and thus p53-targeted therapies are amongst the most encouraging anticancer strategies. In human cancers with wild-type (wt) p53, its inactivation by interaction with murine double minute (MDM)2 and MDMX is a common event. Simultaneous inhibition of the p53 interaction with both MDMs is crucial to restore the tumor suppressor activity of p53. Here we describe the synthesis of the new tryptophanol-derived oxazoloisoindolinone DIMP53-1 and identify its activity as a dual inhibitor of the p53-MDM2/X interactions using a yeast-based assay...
March 10, 2017: Molecular Oncology
https://www.readbyqxmd.com/read/28267263/genetic-analysis-of-uterine-adenosarcomas-and-phyllodes-tumors-of-the-breast
#19
Felipe C Geyer, Kathleen A Burke, Salvatore Piscuoglio, Charlotte K Y Ng, Anastasios D Papanastasiou, Caterina Marchiò, Pier Selenica, Marcia Edelweiss, Melissa P Murray, Edi Brogi, Robert A Soslow, Brian P Rubin, Larry Norton, Jorge S Reis-Filho, Britta Weigelt
Uterine adenosarcomas and breast phyllodes tumors (PTs) are morphologically similar, being composed of stromal projections in a leaf-like fashion lined by epithelial cells. Here we investigated whether their histologic similarities would be mirrored at the genetic level. The previously reported repertoires of somatic genetic alterations found in 19 adenosarcomas and 22 PTs (six benign, six borderline and 10 malignant) were compared. Phyllodes tumors significantly more frequently displayed mutations affecting MED12, the TERT gene promoter and bona fide cancer genes; whereas adenosarcomas harbored a higher rate of MDM2/CDK4 and TERT gene amplifications...
March 7, 2017: Molecular Oncology
https://www.readbyqxmd.com/read/28258651/nmr-metabolomics-highlights-sphingosine-kinase-1-as-a-new-molecular-switch-in-the-orchestration-of-aberrant-metabolic-phenotype-in-cancer-cells
#20
Caterina Bernacchioni, Veronica Ghini, Francesca Cencetti, Lukasz Japtok, Chiara Donati, Paola Bruni, Paola Turano
Strong experimental evidence in animal and cellular models supports a pivotal role of sphingosine kinase-1 (SK1) in oncogenesis. In many human cancers, SK1 levels are upregulated and these increases are linked to poor prognosis in patients. Here, by employing untargeted NMR-based metabolomic profiling combined with functional validations, we report the crucial role of SK1 in the metabolic shift known as the Warburg effect in A2780 ovarian cancer cells. Indeed, expression of SK1 induced a high glycolytic rate, characterized by increased levels of lactate along with increased expression of the proton/monocarboxylate symporter MCT1, and decreased oxidative metabolism, associated with the accumulation of intermediates of the tricarboxylic acid cycle and reduction in CO2 production...
March 4, 2017: Molecular Oncology
journal
journal
41656
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"